Pharma BD Deal Intelligence
A durable but unglamorous asset buy: Cephalon paid $70M for worldwide (ex-Asia) rights to TRISENOX from Cell Therapeutics in 2005. The oncology drug quietly kept clearing milestone thresholds for over a decade, proving to be a persistent niche cash-flow earner rather than a shelved asset.
A small, unglamorous asset buy that quietly paid for itself many times over as a durable oncology cash-flow product
Full analysis, sources & comparables →The transaction was structured for '$70 million in cash, and possible future milestones of up to $100 million,' covering 'worldwide marketing, sales and…
Cell Therapeutics 'received about $29 million' from the initial sale, with cumulative Trisenox revenue of $81.3 million by Q3 2005; by 2003 'approximately…
Cephalon CEO Frank Baldino Jr. framed the deal as building 'a fully integrated oncology business' alongside TREANDA and CEP-701; under his leadership Cephalon…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cephalon acquires worldwide rights (ex-Asia) to TRISENOX (arsenic trioxide) from Cell Therapeutics. Oncology asset deal.
A small, unglamorous asset buy that quietly paid for itself many times over as a durable oncology cash-flow product
Assessment window: 15yr post-close.
600 US cases/yr · $27M Trisenox worldwide sales 2004 ($26.6M)
Acute promyelocytic leukemia (APL) is a rare, aggressive subtype of AML defined by the t(15;17) PML-RARα fusion. Without treatment it is rapidly fatal due to disseminated intravascular coagulation, but with all-trans retinoic acid (ATRA) plus arsenic trioxide it has become one of the most curable acute leukemias — long-term cure rates exceed 90% in low-risk disease.
When Cephalon acquired Trisenox (arsenic trioxide) on June 13, 2005, the APL standard of care was ATRA-based induction (Vesanoid/tretinoin, Roche) with anthracycline chemotherapy, with arsenic trioxide reserved for relapsed/refractory disease per its 2000 FDA approval. Trisenox had no direct competitor — it was the only marketed inorganic arsenic for APL. Cephalon paid '$70 million in cash, and possible future milestones of up to $100 million' (PharmaTimes, June 2005), with worldwide 2004 sales of $26.6 million per the SEC press release. CEO Frank Baldino positioned the deal as part of building 'a fully integrated oncology business' alongside Treandа (bendamustine) and CEP-701. Use expanded over the decade as Lo-Coco's pivotal APL0406 trial (NEJM 2013) established frontline ATRA+ATO as superior to ATRA+chemo, lifting Trisenox into curative regimens. Generic arsenic trioxide entered the US in 2018 (Fresenius Kabi). Teva acquired Cephalon for $6.8B in 2011, inheriting Trisenox; the franchise faded against generics but cemented arsenic trioxide as a curative pillar in APL. See https://pharmatimes.com/news/cephalon_buys_trisenox_for_170m_998108/.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cephalon Inc. / Cell Therapeutics, Inc. (this deal) | 2005 | $70M | 74 |
| Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) | 2000 | $450M | 89 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Cephalon Inc. / Group Lafon (France) | 2001 | $450M | 80 |
| Cephalon Inc. / Anesta Corp. | 2001 | $444M | 65 |
| Cephalon Inc. / Anesta Corp. | 2000 | $444M | 64 |
| Cephalon Inc. / Zeneus Holdings Limited (Zeneus Pharma) | 2005 | $360M | 63 |
← Browse all deals · How we score deals
More: 2005 deals · Cephalon Inc. deals